10月27日 - ** 药物开发商PepGenPEPG.O股价上涨21%，报收于5.53美元；Dyne TherapeuticsDYN.O上涨37.5%，报收于23.54美元。
** 竞争对手 Avidity (link) Biosciences RNA.O周日同意被瑞士制药商诺华NOVN.S以约 120 亿美元现金收购，以加强其治疗罕见肌肉疾病的产品组合。
** Pepgen和Dyne目前也在开发治疗罕见肌肉疾病的药物，如1型肌营养不良症。
** 我们预计 DYN 明天的交易将大幅走高，因为其平台相似，不会大幅落后于 RNA，且市值为 24 亿美元。
** 包括盘中走势在内，DYN上涨1.8%，PEPG年初至今上涨47.8%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.